Dr. Talaat’s current research focuses on clinical trials of vaccines for potential pandemic influenza strains. At the Center for Immunization Research, she conducts phase I and II clinical trials of vaccine candidates for many diverse pathogens. As part of the Pandemic Influenza Preparedness and Response Plan, she plans and executes phase I trials evaluating the safety and immunogenicity of a number of influenza vaccine candidates targeting strains with pandemic potential. She is also trained in infectious diseases and parasitology, and she retains an interest in tropical medicine and international health.
Immune and Hormone Response to Influenza Vaccine
Phase 2b Challenge Study with the Bioconjugate Vaccine Felxyn2a
Talaat KR, Karron RA, Luke CJ, Thumar B, McMahon BA, Chen GL, Lamirande EW, Jin H, Coelingh KL, Kemble G and Subbarao K. “An open label Phase 1 trial of a live attenuated H6N1 influenza virus vaccine in healthy adults.” Vaccine. 2011 Apr 12;29(17):3144-8. doi: 10.1016/j.vaccine.2011.02.043. Epub 2011 Mar 4.
Ramanathan R, Talaat KR, Fedorko DP, Mahanty S and Nash TE. “A species-specific approach to the use of non-antimony treatments for Cutaneous Leishmaniasis.” Am J Trop Med Hyg. 2011;84(1):109-17.
Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, Jeanfreau RJ, Ghosh MR, Kabongo ML, Gittleson C and Karron RA. “A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults.” J Infectious Diseases. 2010;202(9): 1327-37.
Talaat KR, Rothman JA, Cohen JI, Santi M, Rorke-Adams LB, Choi JK, Guzman M, Zimmerman R, Nallasamy S, Brucker A, Quezado M, Pittaluga S, Patronas NJ, Klion AD and Nichols KE. “Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein Barr virus infection.” Pediatric Blood and Cancer. 2009;53(6):1120-3.
Talaat KR, Karron RA, Callahan KA, Luke C, DiLorenzo S, Chen, G., Lamirande, E., Jin, H., Coelingh, K., Kemble, G., and Subbarao, K. “A live attenuated H7N3 influenza virus vaccine is well-tolerated and immunogenic in healthy adults.” Vaccine. 2009;27:3744-3753.